Quintiles To Manage Blepharitis Trial

InSite Vision Selects CRO for DOUBle Trial

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

InSite Vision has selected Quintiles to manage the DOUBle Phase III trial of AzaSite Plus and DexaSite for the treatment of blepharitis. In May 2011, InSite Vision obtained a Special Protocol Assessment (SPA) from the FDA for the DOUBle Trial. AzaSite Plus and DexaSite are formulated with the company’s proprietary DuraSite drug delivery platform: AzaSite Plus combines dexamethasone 0.1% with the antibiotic AzaSite (azithromycin 1% ophthalmic solution) in DuraSite and DexaSite combines dexametha...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters